The PRR indicating the statistical association between a drug and colitis was ~3 times higher for ipilimumab (the anti-CTLA-4 drug), compared to the PRRs for nivolumab and pembrolizumab (anti-PD-1 drugs). The gene discussed is CTLA4; the disease is colitis.